Jonathan Collins : Yeah, thank you for that Peter. I’ll touch on the other two segments. So, on A&G, it is the largest transactional quarter of the year. So it’s an important quarter that signs there within that market are good from a talent or a school year budgeting standpoint, particularly in the US we’re seeing good signs there. And that helped lead to a solid performance in Q3. But there’s a plenty of work left to do in the next couple of months to make sure that we get our share or more than our fair share of that funding between now and the end of the year. But I would say the overall forces in that area are positive. On the life sciences side, you raised a good point on the comps. We had a pretty good performance in real-world data in the fourth quarter of last year.
Q3 of last year was very soft. That’s why we saw transactional growth in Q3 of this year. So we are expecting real-world data sales to be down in the fourth quarter, which will pressure of the life sciences transactional business. Certainly, some of that is the economic forces we just talked about. But in addition to that, we’re really focused on building out a solution set that we’re going to sell directly into the customers and being a bit more selective as we’ve talked about with where we sell our data. So I think both of those are going to have an impact in Q4. And then on the commercialization side, there are a number of other transactions that we offer to aid in commercialization. And we expect there’s going to be some year-over-year pressure on those due to the drug approvals that we saw last year.
We’ll talk more about it in a few months, but as we look in the next year, that’s an area that we think will be a modest tailwind for us. So drug approvals in the US are up over the prior year. So we should see some improvement in commercial budgets going into 2024. But we’ll give some more color on that and a few months. Thank you.
Peter Christiansen : Thank you.
Operator: Our next question comes from the line of Shlomo Rosenthal [Ph] with Stifel. Shlomo, your line is now open.
Unidentified Analyst: Thank you. Jonathan, I want to ask a little bit about some of the contract movements that we’re seeing. There was commentary about on the LS&H business impact of midterm cancellations and kind of renewals like, what does that mean exactly? And are you getting cancellations? And then you can just give us a little bit more color as to why the USPTO contract, what that gets away? Is there any concerns or anything over there? I would assume that’s a pretty big contract with the marquee customers. So any, just color on what’s going on amongst all these different contract movements would be helpful?
Jonathan Gear : Sure, I’ll start and answer your USPTO and I’ll pass to Mr. Collins answer your question on LS&H. On the USPTO and we have a talk about this because obviously, the government contract was public. And so, all this is in the public domain. But they have be a long-term partner and customer of ours. Great relationship with the USPTO in Alexandria. And they awarded – we’ve been – we particular contract, they’ve awarded us an enhanced contract to us and another provider earlier in the year. So it was a consolidation of partners to support them. So one who did not win that contested it and so that then went through a process, a government review process. And we just recently received word on the back of with the confident with their process they have awarded as the original enhanced contract.
So we were never concerns that was losing it. It was a larger contract that was just delayed because any appropriate government review is under process. So we feel very good on the outcome. It has delayed by a little over a quarter the benefit of that. So we’ll see it coming in early next year. But that has not been confirmed. Jonathan, I’ll pass to you on the LS&H.
